Tofacitinib [477600-75-2]

Katalog-Nummer HY-40354-500mg

Size : 500mg

Marke : MedChemExpress

Weitere Informationen anfordern

Contact local distributor :


Telefonnummer : +1 850 650 7790

Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Tofacitinib Chemische Struktur

Tofacitinib Chemische Struktur

CAS. Nr. : 477600-75-2

This product is a controlled substance and not for sale in your territory.

Based on 59 publication(s) in Google Scholar

Other Forms of Tofacitinib:

  • (3S,4S)-Tofacitinib In-stock
  • Tofacitinib citrate In-stock
  • (3S,4R)-Tofacitinib Angebot einholen
  • (3R,4S)-Tofacitinib Angebot einholen
  • Tofacitinib-13C3 Angebot einholen
  • Tofacitinib (Standard) Angebot einholen

    Tofacitinib purchased from MedChemExpress. Usage Cited in: Pulm Pharmacol Ther. 2017 Apr;43:60-67.  [Abstract]

    Effect of Tofacitinib administered 1 h before LPS challenge. (A) Effect of different doses of Tofacitinib on STAT3 activation in lung homogenates obtained 30 min after LPS challenge. (B) Effect of different doses of Tofacitinib on STAT3 activation in lung homogenates obtained 4 h after LPS challenge.

    Alle JAK Isoform-spezifische Produkte anzeigen:

    Alle Isoformen anzeigen
    JAK1 JAK2 JAK3 Tyk2 JAK
    Beschreibung

    Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively.

    IC50 & Target[1]

    JAK3

    1 nM (IC50)

    JAK2

    20 nM (IC50)

    JAK1

    112 nM (IC50)

    Rock-II

    3400 nM (IC50)

    Lck

    3870 nM (IC50)

    Cellular Effect
    Cell Line Type Value Description References
    A549 IC50
    0.1 μM
    Compound: Tofacitinib
    Antiproliferative activity against human A549 cells incubated for 24 to 48 hrs by CCK8 assay
    Antiproliferative activity against human A549 cells incubated for 24 to 48 hrs by CCK8 assay
    [PMID: 33234343]
    BaF3 IC50
    0.026 μM
    Compound: 20, CP-690550
    Inhibition of TEL-fused JAK1 expressed in Ba/F3 cells assessed as inhibition of STAT5 phosphorylation after 60 mins by AlphaScreen assay
    Inhibition of TEL-fused JAK1 expressed in Ba/F3 cells assessed as inhibition of STAT5 phosphorylation after 60 mins by AlphaScreen assay
    [PMID: 22087750]
    BaF3 IC50
    0.054 μM
    Compound: 20, CP-690550
    Inhibition of TEL-fused JAK3 expressed in Ba/F3 cells assessed as inhibition of STAT5 phosphorylation after 60 mins by AlphaScreen assay
    Inhibition of TEL-fused JAK3 expressed in Ba/F3 cells assessed as inhibition of STAT5 phosphorylation after 60 mins by AlphaScreen assay
    [PMID: 22087750]
    BaF3 IC50
    0.265 μM
    Compound: 20, CP-690550
    Inhibition of TEL-fused JAK2 expressed in Ba/F3 cells assessed as inhibition of STAT5 phosphorylation after 60 mins by AlphaScreen assay
    Inhibition of TEL-fused JAK2 expressed in Ba/F3 cells assessed as inhibition of STAT5 phosphorylation after 60 mins by AlphaScreen assay
    [PMID: 22087750]
    BaF3 IC50
    1.2 μM
    Compound: 20, CP-690550
    Inhibition of TEL-fused TYK2 expressed in Ba/F3 cells assessed as inhibition of STAT5 phosphorylation after 60 mins by AlphaScreen assay
    Inhibition of TEL-fused TYK2 expressed in Ba/F3 cells assessed as inhibition of STAT5 phosphorylation after 60 mins by AlphaScreen assay
    [PMID: 22087750]
    BaF3 IC50
    1574 nM
    Compound: CP-690550
    Antiproliferative activity against mouse BAF3 cells expressing TEL-JAK2 kinase after 72 hrs by alamar blue assay
    Antiproliferative activity against mouse BAF3 cells expressing TEL-JAK2 kinase after 72 hrs by alamar blue assay
    [PMID: 19762238]
    BaF3 IC50
    177.3 nM
    Compound: 2
    Antiproliferative activity against mouse BaF3 cells harboring JAK3 M5111 mutant assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BaF3 cells harboring JAK3 M5111 mutant assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    [PMID: 35860875]
    BaF3 IC50
    4154.3 nM
    Compound: 2
    Antiproliferative activity against mouse BaF3 cells harboring TEL-JAK1 fusion protein assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BaF3 cells harboring TEL-JAK1 fusion protein assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    [PMID: 35860875]
    BaF3 IC50
    516.5 nM
    Compound: 2
    Antiproliferative activity against mouse BaF3 parent cell measured after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BaF3 parent cell measured after 72 hrs by CCK-8 assay
    [PMID: 35860875]
    BaF3 IC50
    570 nM
    Compound: CP-690550
    Antiproliferative activity against mouse BAF3 cells expressing TEL-JAK3 kinase after 72 hrs by alamar blue assay
    Antiproliferative activity against mouse BAF3 cells expressing TEL-JAK3 kinase after 72 hrs by alamar blue assay
    [PMID: 19762238]
    BaF3 IC50
    8884.6 nM
    Compound: 2
    Antiproliferative activity against mouse BaF3 cells harboring TEL-JAK2 fusion protein assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BaF3 cells harboring TEL-JAK2 fusion protein assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    [PMID: 35860875]
    CTLL IC50
    48 nM
    Compound: 2, CP-690550
    Inhibition of Jak3-mediated IL2-induced Stat5 phosphorylation in mouse CTLL cells by cell-based assay
    Inhibition of Jak3-mediated IL2-induced Stat5 phosphorylation in mouse CTLL cells by cell-based assay
    [PMID: 21155605]
    HEL IC50
    4724 nM
    Compound: Tofacitinib
    Inhibition of JAK2 V617F mutant in human HEL cells after 1 hr
    Inhibition of JAK2 V617F mutant in human HEL cells after 1 hr
    [PMID: 27771180]
    HEL IC50
    5.2 μM
    Compound: Tofacitinib
    Antiproliferative activity against human HEL cells harboring JAK2 V617F mutant measured after 48 hrs by CellTiter-Glo assay
    Antiproliferative activity against human HEL cells harboring JAK2 V617F mutant measured after 48 hrs by CellTiter-Glo assay
    [PMID: 30846405]
    HeLa IC50
    0.04 μM
    Compound: Tofacitinib
    Antiproliferative activity against human Hela cells incubated for 24 to 48 hrs by CCK8 assay
    Antiproliferative activity against human Hela cells incubated for 24 to 48 hrs by CCK8 assay
    [PMID: 33234343]
    HepG2 IC50
    0.11 μM
    Compound: Tofacitinib
    Antiproliferative activity against human HepG2 cells incubated for 24 to 48 hrs by CCK8 assay
    Antiproliferative activity against human HepG2 cells incubated for 24 to 48 hrs by CCK8 assay
    [PMID: 33234343]
    HFF IC50
    > 10000 nM
    Compound: 1
    Inhibition of HFF proliferation after 72 hrs by [3H]thymidine incorporation assay
    Inhibition of HFF proliferation after 72 hrs by [3H]thymidine incorporation assay
    [PMID: 21105711]
    HFF IC50
    > 10000 nM
    Compound: CP-690550
    Inhibition of fetal calf serum-induced proliferation of human foreskin fibroblast assessed as [3H]thymidine incorporation after 4 days by scintillation counting
    Inhibition of fetal calf serum-induced proliferation of human foreskin fibroblast assessed as [3H]thymidine incorporation after 4 days by scintillation counting
    [PMID: 14593182]
    Jurkat IC50
    > 5000 nM
    Compound: 2, CP-690550
    Inhibition of antiTCR/antiCD28-stimulated IL2 production in human Jurkat cells by measuring bioluminescence
    Inhibition of antiTCR/antiCD28-stimulated IL2 production in human Jurkat cells by measuring bioluminescence
    [PMID: 21155605]
    Jurkat IC50
    7840 nM
    Compound: CP-690550
    Inhibition of anti-CD3/anti-CD28-induced IL2 production in human Jurkat cells after 24 hrs by scintillation counting
    Inhibition of anti-CD3/anti-CD28-induced IL2 production in human Jurkat cells after 24 hrs by scintillation counting
    [PMID: 14593182]
    MCF7 IC50
    > 100 μM
    Compound: Tofacitinib
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    [PMID: 32682202]
    MGC-803 IC50
    > 100 μM
    Compound: Tofacitinib
    Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    [PMID: 32682202]
    NCI-H1975 IC50
    > 100 μM
    Compound: Tofacitinib
    Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    [PMID: 32682202]
    PBMC IC50
    39 nM
    Compound: Tofacitinib
    Inhibition IL-7-indcued STAT5 phosphorylation in human PBMC cells by flow cytometry
    Inhibition IL-7-indcued STAT5 phosphorylation in human PBMC cells by flow cytometry
    [PMID: 26927423]
    PC-9 IC50
    > 100 μM
    Compound: Tofacitinib
    Antiproliferative activity against human PC-9 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human PC-9 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    [PMID: 32682202]
    Sf21 IC50
    0.0012 μM
    Compound: 1; CP-690,550
    Inhibition of N-terminal GST-fused human JAK2 (880 to end residues) expressed in baculovirus infected Sf21 cells using TK-substrate-biotin as substrate incubated for 60 mins in presence of ATP by fluorescence method
    Inhibition of N-terminal GST-fused human JAK2 (880 to end residues) expressed in baculovirus infected Sf21 cells using TK-substrate-biotin as substrate incubated for 60 mins in presence of ATP by fluorescence method
    [PMID: 32511913]
    Sf21 IC50
    0.004 μM
    Compound: CP690, 550
    Inhibition of JAK2 (unknown origin) expressed in SF21 cells using Biotin-KAIETDKEYYTVKD as substrate and [33Pgamma]ATP incubated for 10 mins prior to substrate addition measured after 30 mins by Topcount analysis
    Inhibition of JAK2 (unknown origin) expressed in SF21 cells using Biotin-KAIETDKEYYTVKD as substrate and [33Pgamma]ATP incubated for 10 mins prior to substrate addition measured after 30 mins by Topcount analysis
    [PMID: 23541670]
    Sf21 IC50
    4.1 nM
    Compound: 2
    Inhibition of recombinant human C-terminal 6His-tagged JAK2 (808 to end amino acids) expressed in Sf21 cells measured after 1 hr in presence of ATP by TR-FRET assay
    Inhibition of recombinant human C-terminal 6His-tagged JAK2 (808 to end amino acids) expressed in Sf21 cells measured after 1 hr in presence of ATP by TR-FRET assay
    [PMID: 27555284]
    Sf9 IC50
    0.0006 μM
    Compound: 20, CP-690550
    Inhibition of human recombinant N-terminal GST-tagged JAK3 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay
    Inhibition of human recombinant N-terminal GST-tagged JAK3 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay
    [PMID: 22087750]
    Sf9 IC50
    0.0011 μM
    Compound: 1; CP-690,550
    Inhibition of human JAK3 (780 to end residues) expressed in baculovirus infected Sf9 cells using TK-substrate-biotin as substrate incubated for 60 mins in presence of ATP by fluorescence method
    Inhibition of human JAK3 (780 to end residues) expressed in baculovirus infected Sf9 cells using TK-substrate-biotin as substrate incubated for 60 mins in presence of ATP by fluorescence method
    [PMID: 32511913]
    Sf9 IC50
    0.003 μM
    Compound: 20, CP-690550
    Inhibition of human recombinant N-terminal GST-tagged JAK1 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay
    Inhibition of human recombinant N-terminal GST-tagged JAK1 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay
    [PMID: 22087750]
    Sf9 IC50
    0.004 μM
    Compound: 20, CP-690550
    Inhibition of human recombinant N-terminal GST-tagged JAK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay
    Inhibition of human recombinant N-terminal GST-tagged JAK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay
    [PMID: 22087750]
    Sf9 IC50
    0.052 μM
    Compound: 20, CP-690550
    Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay
    Inhibition of human recombinant N-terminal GST-tagged TYK2 expressed in Sf9 cells using Biotin-LC-EQEDEPEGDYFEWLE as substrate after 90 mins by TR-FRET assay
    [PMID: 22087750]
    Sf9 IC50
    1 nM
    Compound: 1
    Inhibition of GST-tagged human JAK3 catalytic domain expressed in Sf9 cells by ELISA
    Inhibition of GST-tagged human JAK3 catalytic domain expressed in Sf9 cells by ELISA
    [PMID: 21105711]
    Sf9 IC50
    1 nM
    Compound: CP-690550
    Inhibition of human recombinant GST-tagged JH1 domain (785 to1125) of JAK3 expressed in insect Sf9 cells by ELISA
    Inhibition of human recombinant GST-tagged JH1 domain (785 to1125) of JAK3 expressed in insect Sf9 cells by ELISA
    [PMID: 14593182]
    Sf9 IC50
    110 nM
    Compound: 18m
    Inhibition of GST-tagged human JAK1 catalytic domain expressed in Sf9 cells by ELISA
    Inhibition of GST-tagged human JAK1 catalytic domain expressed in Sf9 cells by ELISA
    [PMID: 21105711]
    Sf9 IC50
    3.3 nM
    Compound: 18m
    Inhibition of GST-tagged human JAK3 catalytic domain expressed in Sf9 cells by ELISA
    Inhibition of GST-tagged human JAK3 catalytic domain expressed in Sf9 cells by ELISA
    [PMID: 21105711]
    Splenocyte IC50
    23 nM
    Compound: 1
    Immunosuppressive activity in Lewis rat splenocytes assessed as inhibition of concanavalin A-induced IL-2 receptor expression incubated for 3 days by alamarBlue assay
    Immunosuppressive activity in Lewis rat splenocytes assessed as inhibition of concanavalin A-induced IL-2 receptor expression incubated for 3 days by alamarBlue assay
    [PMID: 28789911]
    T-cell IC50
    0.016 μM
    Compound: 1; CP-690,550
    Inhibition of IL2-induced human T cell proliferation preincubated for 30 mins followed by IL2 stimulation and measured after 3 days by [3H]thymidine incorporation based scintillation counting method
    Inhibition of IL2-induced human T cell proliferation preincubated for 30 mins followed by IL2 stimulation and measured after 3 days by [3H]thymidine incorporation based scintillation counting method
    [PMID: 32511913]
    T-cell IC50
    11 nM
    Compound: CP-690550
    Inhibition of IL2-induced proliferation of human T cells assessed as [3H]thymidine incorporation after 72 hrs by scintillation counting
    Inhibition of IL2-induced proliferation of human T cells assessed as [3H]thymidine incorporation after 72 hrs by scintillation counting
    [PMID: 14593182]
    T-cell IC50
    11 nM
    Compound: 1
    Inhibition of human IL2-dependent T cell blast proliferation assessed as reduction in [3H]thymidine incorporation after 72 hrs post dose IL2 blast assay
    Inhibition of human IL2-dependent T cell blast proliferation assessed as reduction in [3H]thymidine incorporation after 72 hrs post dose IL2 blast assay
    [PMID: 21105711]
    T-cell IC50
    115 nM
    Compound: CP-690550
    Inhibition of allogenic cells-stimulated proliferation in mouse T cells by mixed lymphocyte reaction method
    Inhibition of allogenic cells-stimulated proliferation in mouse T cells by mixed lymphocyte reaction method
    [PMID: 14593182]
    T-cell IC50
    16 nM
    Compound: 1
    Inhibition of IL-2 induced human T cell proliferation preincubated with compound for 30 mins followed by IL-2 induction and measured after 3 days in the presence of [3H]thymidine by scintillation counter analysis
    Inhibition of IL-2 induced human T cell proliferation preincubated with compound for 30 mins followed by IL-2 induction and measured after 3 days in the presence of [3H]thymidine by scintillation counter analysis
    [PMID: 32120325]
    T-cell IC50
    2 nM
    Compound: Tofacitinib
    Antiproliferative activity against rat T cells cultured with Concanavalin A for 24 hrs assessed inhibition of IL-2-stimulated cell proliferation after 72 hrs by MTS assay
    Antiproliferative activity against rat T cells cultured with Concanavalin A for 24 hrs assessed inhibition of IL-2-stimulated cell proliferation after 72 hrs by MTS assay
    [PMID: 30853331]
    T-cell IC50
    23 nM
    Compound: 1, CP-690,550
    Inhibition of JAK1/JAK3 in Lewis rat splenocytes assessed as reduction in IL2-induced T cell proliferation incubated for 3 days by alamar blue assay
    Inhibition of JAK1/JAK3 in Lewis rat splenocytes assessed as reduction in IL2-induced T cell proliferation incubated for 3 days by alamar blue assay
    [PMID: 26059596]
    T-cell IC50
    40 nM
    Compound: 18m
    Inhibition of human IL2-dependent T cell blast proliferation assessed as reduction in [3H]thymidine incorporation after 72 hrs post dose IL2 blast assay
    Inhibition of human IL2-dependent T cell blast proliferation assessed as reduction in [3H]thymidine incorporation after 72 hrs post dose IL2 blast assay
    [PMID: 21105711]
    T-cell IC50
    57 nM
    Compound: CP-690550
    Inhibition of allogenic cells-stimulated proliferation in monkey T cells by mixed lymphocyte reaction method
    Inhibition of allogenic cells-stimulated proliferation in monkey T cells by mixed lymphocyte reaction method
    [PMID: 14593182]
    T-cell IC50
    87 nM
    Compound: CP-690550
    Inhibition of allogenic cells-stimulated proliferation in human T cells by mixed lymphocyte reaction method
    Inhibition of allogenic cells-stimulated proliferation in human T cells by mixed lymphocyte reaction method
    [PMID: 14593182]
    TF-1 IC50
    0.095 μM
    Compound: Tofacitinib
    Inhibition of JAK2 in GMCSF-stimulated human TF1 cells assessed as suppression of STAT5 phosphorylation preincubated for 2 hrs followed by GMCSF stimulation for 50 mins by FACS reader analysis
    Inhibition of JAK2 in GMCSF-stimulated human TF1 cells assessed as suppression of STAT5 phosphorylation preincubated for 2 hrs followed by GMCSF stimulation for 50 mins by FACS reader analysis
    [PMID: 27130359]
    TF-1 IC50
    0.12 μM
    Compound: 20
    Inhibition of JAK2 in human STAT5-irf1-bla TF1 cells assessed as reduction in EPO-induced STAT5-signalling pre-incubated for 1 hrs before EPO addition and further incubated for 4 hrs fluorescence based assay
    Inhibition of JAK2 in human STAT5-irf1-bla TF1 cells assessed as reduction in EPO-induced STAT5-signalling pre-incubated for 1 hrs before EPO addition and further incubated for 4 hrs fluorescence based assay
    [PMID: 32462873]
    TF-1 IC50
    2.6 μM
    Compound: Tofacitinib
    Antiproliferative activity against JAK2 wild-type human TF1 cells measured after 48 hrs by CellTiter-Glo assay
    Antiproliferative activity against JAK2 wild-type human TF1 cells measured after 48 hrs by CellTiter-Glo assay
    [PMID: 30846405]
    TF-1 EC50
    43 nM
    Compound: 1, CP-690,550, Tofacitinib, Xeljanz
    Inhibition of JAK1 in human TF1 cells assessed as inhibition of IL6-induced STAT3 phosphorylation incubated for 20 mins followed by IL6 challenge for 30 mins in presence of whole blood
    Inhibition of JAK1 in human TF1 cells assessed as inhibition of IL6-induced STAT3 phosphorylation incubated for 20 mins followed by IL6 challenge for 30 mins in presence of whole blood
    [PMID: 23659214]
    TF-1 EC50
    53 nM
    Compound: 1, CP-690,550, Tofacitinib, Xeljanz
    Inhibition of JAK1 in human TF1 cells assessed as inhibition of IL6-induced STAT3 phosphorylation incubated for 20 mins followed by IL6 challenge for 30 mins
    Inhibition of JAK1 in human TF1 cells assessed as inhibition of IL6-induced STAT3 phosphorylation incubated for 20 mins followed by IL6 challenge for 30 mins
    [PMID: 23659214]
    TF-1 EC50
    53 nM
    Compound: 1, CP-690550
    Inhibition of JAK1 in human TF1 cells assessed as inhibition of IL6-induced STAT3 phosphorylation incubated for 20 mins prior to IL6-induction measured after 30 to 45 mins
    Inhibition of JAK1 in human TF1 cells assessed as inhibition of IL6-induced STAT3 phosphorylation incubated for 20 mins prior to IL6-induction measured after 30 to 45 mins
    [PMID: 22698084]
    TF-1 EC50
    93 nM
    Compound: 1, CP-690,550, Tofacitinib, Xeljanz
    Inhibition of JAK2 in human TF1 cells assessed as inhibition of EPO-induced STAT5 phosphorylation incubated for 20 mins followed by IL6 challenge for 30 mins
    Inhibition of JAK2 in human TF1 cells assessed as inhibition of EPO-induced STAT5 phosphorylation incubated for 20 mins followed by IL6 challenge for 30 mins
    [PMID: 23659214]
    TF-1 EC50
    93 nM
    Compound: 1, CP-690550
    Inhibition of JAK2 in human TF1 cells assessed as inhibition of EPO-induced STAT5 phosphorylation incubated for 20 mins prior to EPO-induction measured after 30 to 45 mins
    Inhibition of JAK2 in human TF1 cells assessed as inhibition of EPO-induced STAT5 phosphorylation incubated for 20 mins prior to EPO-induction measured after 30 to 45 mins
    [PMID: 22698084]
    THP-1 IC50
    0.9 μM
    Compound: Tofacitinib
    Cytotoxicity against IL-4 induced JAK1/3 activated human THP1 cells preincubated for 1 hr followed by IL-4 induction and measured after 1 hr by CellTiter-Glo assay
    Cytotoxicity against IL-4 induced JAK1/3 activated human THP1 cells preincubated for 1 hr followed by IL-4 induction and measured after 1 hr by CellTiter-Glo assay
    [PMID: 30846405]
    THP1-Dual IC50
    24.8 nM
    Compound: Tofacitinib
    Inhibition of LPS induced ISG activation in human THP1-Dual cells pretreated with LPS-B5 for 3 hrs followed by compound addition incubated for 24 hrs
    Inhibition of LPS induced ISG activation in human THP1-Dual cells pretreated with LPS-B5 for 3 hrs followed by compound addition incubated for 24 hrs
    [PMID: 36053746]
    U-251 IC50
    0.33 μM
    Compound: Tofacitinib
    Antiproliferative activity against human U-251 cells incubated for 24 to 48 hrs by CCK8 assay
    Antiproliferative activity against human U-251 cells incubated for 24 to 48 hrs by CCK8 assay
    [PMID: 33234343]
    U-937 IC50
    122.4 nM
    Compound: 2
    Antiproliferative activity against human U-937 cells harboring JAK3 M511135 mutant assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    Antiproliferative activity against human U-937 cells harboring JAK3 M511135 mutant assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay
    [PMID: 35860875]
    In Vitro

    Tofacitinib (CP-690550) citrate binds potentially at JAK3 and JAK2 as 2.2 nM and 5 nM (Kd). The report includes additional binding for Tofacitinib at Camk1 (Kd of 5,000 nM), DCamkL3 (Kd of 4.5 nM), Mst2 (Kd of 4,300 nM), Pkn1 (Kd of 200 nM), Rps6ka2 (Kin.Dom.2-C-terminal) (Kd of 1,400 nM), Rps6ka6 (Kin.Dom.2-C-terminal) (Kd of 1,200 nM), Snark (Kd of 420 nM), Tnk1 (Kd of 640 nM) and Tyk2 (Kd of 620 nM)[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Animals that are treated with Tofacitinib show a significantly lower production of anti-drug antibodies (ADAs) compare with PEG-treated control mice (for five weeks after initial immunization, p<0.01, n=8). Moreover ADAs become detectable earliest on day 28. A difference of 1000- to 200-fold in titers to SS1P is apparent from days 21 through 35, respectively. Compare to SS1P, mice injected with keyhole limpet hemocyanin (KLH) generate a more rapid antibody response. Yet, the administration of Tofacitinib reduces anti-KLH titers compare to controls (p<0.05 on day 21, p<0.01 on day 28, respectively, n=5). Reductions in titers ranged from 5000- to 250-fold from days 21 through 28, respectively[2]. Based on previous dose-response studies, a daily dose of Tofacitinib of 6.2 mg/kg is selected to provide 80% inhibition of hind paw volume and plasma exposure capable of suppressing the JAK1 and JAK3 signaling pathways for >4 hours[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Klinische Studie
    Molekulargewicht

    312.37

    Formel

    C16H20N6O

    CAS. Nr.

    477600-75-2

    Appearance

    Solid

    Color

    Off-white to light yellow

    SMILES

    O=C(CC#N)N1C[C@H](N(C2=C3C(NC=C3)=NC=N2)C)[C@H](C)CC1

    Versand

    Room temperature in continental US; may vary elsewhere.

    Speicherung
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Lösungsmittel & Löslichkeit
    In Vitro: 

    DMSO : 125 mg/mL (400.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Ethanol : 2.5 mg/mL (8.00 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.2013 mL 16.0067 mL 32.0133 mL
    5 mM 0.6403 mL 3.2013 mL 6.4027 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molaritätsrechner

    • Verdünnungsrechner

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  5% DMSO    40% PEG300    5% Tween-80    50% Saline

      Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution

    • Protocol 2

      Add each solvent one by one:  5% DMSO    95% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  0.5% Methyl cellulose/0.5% Tween-80 in Saline water

      Solubility: 5 mg/mL (16.01 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Reinheit & Dokumentation

    Purity: 99.99%

    Verweise
    • [1]. Jiang JK, et al. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). J Med Chem. 2008 Dec 25;51(24):8012-8.  [Content Brief]

      [2]. Onda M, et al. Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts. J Immunol. 2014 Jul 1;193(1):48-55.  [Content Brief]

      [3]. LaBranche TP, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum. 2012 Nov;64(11):3531-42.  [Content Brief]

      [4]. Calama E, et al. Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS. Pulm Pharmacol Ther. 2017 Apr;43:60-67.  [Content Brief]

    Kinase-Assay
    [1]

    Kinase activity is recorded via a competition binding assay of selected kinases that are fused to a proprietary tag. Measurements of the amount of kinase binds to an immobilized, active-site directed ligand in the presence and absence of the test compound (e.g., Tofacitinib) provide a % of DMSO control for binding of ligand. Activities between 0 and 10 are selected for Kd determinations. Dendrogram representations are generated by an in-house visualization tool designated PhyloChem[1].

    MCE hat die Genauigkeit dieser Methoden nicht unabhängig bestätigt. Sie dienen nur als Referenz.

    Zellassay
    [1]

    Human CD4+ positive cells are enriched from peripheral blood mononuclear cells obtained from a healthy donor by magnetic separation (CD4+ MACS beads). CD4+ cells are activated for 3 days with plate bound anti-CD3 and anti CD28 antibodies (5 ug/mL each), and then expanded for another 4 days in the presence of IL-2 (50 U/mL). Cells are rested overnight in 1% RPMI, and pre-incubated with Tofacitinib or DMSO control for 1 hour at indicated concentrations (5 nM, 50 nM, 500 nM; DMSO concentration is equal in all preparations) and then activated with IL-2 (1000 u/mL) or IL-12 (100 ng/mL) for 15 minutes. Cells (10×106/condition) are lysed in 1% Triton-x lysis buffer and equal amounts of cell lysate are run in NuPage Bis-Tris gel (4-12% gradient). Proteins are transferred onto nitrocellulose membrane. Detection is done with indicated antibodies using Odyssey western blotting system[1].

    MCE hat die Genauigkeit dieser Methoden nicht unabhängig bestätigt. Sie dienen nur als Referenz.

    Tierverwaltung
    [2][3]

    Mice[2]
    Female BALB/c mice (6-8 weeks old) are used. Mice receive Tofacitinib in PEG300 (100 mg/mL) or vehicle alone (PEG300) by osmotic pump infusion (Alzet Model 2004, 0.25 μL/hour, 28 days). Four days prior to immunization, mice are anesthetized and their dorsal surface is shaved. A one cm incision is made on the back to create a subcutaneous pocket and insert the pump. The incision site is closed with wound clips. Mice are injected weekly (i.p.) with SS1P recombinant immunotoxin (RIT; 5 μg/mouse) beginning on day 0; control mice received injections of saline alone. Every week before SS1P or vehicle immunization, 50 μL of blood is drawn to obtain serum samples. Sera are stored at −80°C until analyzed.
    Rats[3]
    Adjuvant-induced arthritis (AIA) is induced in female Lewis rats. Rats are randomized according to hind paw volume and assigned to Tofacitinib or vehicle treatment regimens. Groups of 7-8 rats per treatment group, and normal naive rats (n=4 per group), are euthanized either 4 hours, 4 days, or 7 days after beginning treatment (days 16, 20, and 23 after immunization, respectively). Tofacitinib is suspended in 0.5% methylcellulose/0.025% Tween 20 for in vivo studies. Once-daily oral administration of vehicle or Tofacitinib (6.2 mg/kg) is initiated on day 16 following immunization and continued through day 23. Paw volumes are reassessed 4 and 7 days after the beginning of treatment (days 20 and 23 after immunization, respectively). For micro-computed tomography (micro-CT) imaging, as well as tartrate-resistant acid phosphatase (TRAP) staining in paw tissue, AIA is induced in a separate cohort of Lewis rats.

    MCE hat die Genauigkeit dieser Methoden nicht unabhängig bestätigt. Sie dienen nur als Referenz.

    Verweise
    • [1]. Jiang JK, et al. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). J Med Chem. 2008 Dec 25;51(24):8012-8.  [Content Brief]

      [2]. Onda M, et al. Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts. J Immunol. 2014 Jul 1;193(1):48-55.  [Content Brief]

      [3]. LaBranche TP, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum. 2012 Nov;64(11):3531-42.  [Content Brief]

      [4]. Calama E, et al. Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS. Pulm Pharmacol Ther. 2017 Apr;43:60-67.  [Content Brief]

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    Ethanol / DMSO 1 mM 3.2013 mL 16.0067 mL 32.0133 mL 80.0333 mL
    5 mM 0.6403 mL 3.2013 mL 6.4027 mL 16.0067 mL
    DMSO 10 mM 0.3201 mL 1.6007 mL 3.2013 mL 8.0033 mL
    15 mM 0.2134 mL 1.0671 mL 2.1342 mL 5.3356 mL
    20 mM 0.1601 mL 0.8003 mL 1.6007 mL 4.0017 mL
    25 mM 0.1281 mL 0.6403 mL 1.2805 mL 3.2013 mL
    30 mM 0.1067 mL 0.5336 mL 1.0671 mL 2.6678 mL
    40 mM 0.0800 mL 0.4002 mL 0.8003 mL 2.0008 mL
    50 mM 0.0640 mL 0.3201 mL 0.6403 mL 1.6007 mL
    60 mM 0.0534 mL 0.2668 mL 0.5336 mL 1.3339 mL
    80 mM 0.0400 mL 0.2001 mL 0.4002 mL 1.0004 mL
    100 mM 0.0320 mL 0.1601 mL 0.3201 mL 0.8003 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Tofacitinib Related Classifications

    Help & FAQs

    Keywords:

    Tofacitinib477600-75-2Tasocitinib CP-690550CP690550CP 690550CP-690550JAKApoptosisJanus kinaseInhibitorinhibitorinhibit

    Sie könnten auch an folgenden Produkten interessiert sein:



    Katalog-Nummer
    Beschreibung
    Cond.
    Preis zzgl. MwSt.
    AAH-INF-1-8
     8SampleKit 
    AAH-INF-1-2
     2SampleKit 
    AAM-INF-1-8
     8SampleKit